These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 32961525)

  • 1. Modelling of the
    Bhardwaj R; Wolterbeek HT; Denkova AG; Serra-Crespo P
    Appl Radiat Isot; 2020 Dec; 166():109261. PubMed ID: 32961525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale production of lutetium-177m for the
    Bhardwaj R; Ponsard B; Sarilar M; Wolterbeek B; Denkova A; Serra-Crespo P
    Appl Radiat Isot; 2020 Feb; 156():108986. PubMed ID: 31786419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radionuclide generator-based production of therapeutic 
    Bhardwaj R; Wolterbeek HT; Denkova AG; Serra-Crespo P
    EJNMMI Radiopharm Chem; 2019 Jul; 4(1):13. PubMed ID: 31659496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid phase extraction-based separation of the nuclear isomers
    Bhardwaj R; Wolterbeek HT; Denkova AG; Serra-Crespo P
    Appl Radiat Isot; 2020 Oct; 164():109264. PubMed ID: 32819504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the
    Balzer M; Spiecker F; Bluemel S; Amthauer H; Brenner W; Spreckelmeyer S
    EJNMMI Radiopharm Chem; 2023 Nov; 8(1):37. PubMed ID: 37930495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.
    Bhardwaj R; van der Meer A; Das SK; de Bruin M; Gascon J; Wolterbeek HT; Denkova AG; Serra-Crespo P
    Sci Rep; 2017 Mar; 7():44242. PubMed ID: 28287131
    [No Abstract]   [Full Text] [Related]  

  • 7. Technical note: Quantifying radionuclide residues in hospital wastewater: A case study on [
    Kupitz D; Einspänner E; Wissel H; Volk M; Hohn A; Kreissl MC; Grosser OS
    Med Phys; 2024 Jun; ():. PubMed ID: 38922963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technical note: Assessment of radiation measurement devices for the detection of [
    Kupitz D; Einspänner E; Wissel H; Hohn A; Kreissl MC; Grosser OS
    Med Phys; 2023 Jan; 50(1):590-599. PubMed ID: 36208077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging.
    Gleisner KS; Brolin G; Sundlöv A; Mjekiqi E; Östlund K; Tennvall J; Larsson E
    J Nucl Med; 2015 Jul; 56(7):976-84. PubMed ID: 25999429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of
    Kazakov AG; Ekatova TY; Babenya JS; Belyshev SS; Khankin VV; Kuznetsov AA; Vinokurov SE; Myasoedov BF
    Molecules; 2022 May; 27(10):. PubMed ID: 35630655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry.
    Konijnenberg MW
    Curr Radiopharm; 2015; 8(2):145-9. PubMed ID: 25771362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of lutetium-177 production at the WWR-K research reactor.
    Sairanbayev D; Koltochnik S; Shaimerdenov A; Chakrova Y; Gurin A; Kenzhin Y
    Appl Radiat Isot; 2021 Mar; 169():109561. PubMed ID: 33360502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical optimization of production by deuteron irradiation of high specific activity (177g)Lu suitable for radioimmunotherapy.
    Manenti S; Bonardi ML; Gini L; Groppi F
    Nucl Med Biol; 2014; 41(5):407-9. PubMed ID: 24666720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dealing with dry waste disposal issues associated with
    Prevot S; Dygaï-Cochet I; Riedinger JM; Vrigneaud JM; Quermonne M; Gallet M; Cochet A
    EJNMMI Phys; 2023 Jan; 10(1):3. PubMed ID: 36622501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excitation function for deuteron induced nuclear reactions on natural ytterbium for production of high specific activity 177g Lu in no-carrier-added form for metabolic radiotherapy.
    Manenti S; Groppi F; Gandini A; Gini L; Abbas K; Holzwarth U; Simonelli F; Bonardi M
    Appl Radiat Isot; 2011 Jan; 69(1):37-45. PubMed ID: 20801665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gamma-ray emission probabilities in the decay of (177m)Lu.
    Kondev FG; Ahmad I; Carpenter MP; Greene JP; Janssens RV; Lauritsen T; Seweryniak D; Zhu S; Lalkovski SP; Chowdhury P
    Appl Radiat Isot; 2012 Sep; 70(9):1867-70. PubMed ID: 22401939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production, quality control, biodistribution assessment and preliminary dose evaluation of (177)Lu-PDTMP as a possible bone palliative agent.
    Yousefnia H; Jalilian AR; Zolghadri S; Ghannadi-Maragheh M
    Nucl Med Commun; 2014 Jan; 35(1):99-107. PubMed ID: 24162837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
    Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
    Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
    Abbasi IA
    Nucl Med Biol; 2011 Apr; 38(3):417-25. PubMed ID: 21492790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.